Nothing said here yet.
to join the conversation.
| FOSTER JAMES CDirector | Sell | 24,042 | $8.4M | Thu, Oct 22 |
| Parisotto Shannon MCEVP, Disc & Safety Assessment | Sell | 2,156 | $742.5K | Wed, Oct 21 |
| Parisotto Shannon MCEVP, Disc & Safety Assessment | Sell | 981 | $302.6K | Mon, Oct 5 |
| Coleman GlennEVP & Chief Financial Officer | Buy | 10 | $3.0K | Wed, Sep 30 |
| FOSTER JAMES CDirector | Sell | 33,561 | $10.1M | Tue, Aug 25 |
| Parisotto Shannon MCEVP, Disc & Safety Assessment | Sell | 2,039 | $599.7K | Wed, Aug 19 |
| Andrews Nancy CDirector | Sell | 573 | $163.4K | Tue, Aug 18 |
Charles River Laboratories International has become a talking point after a sharp multi‑year rally, which naturally raises a harder question for you as an investor: Is the current share price still grounded in the cash flows the business can generate, or has…
Charles River Laboratories International (NYSE:CRL) agreed to deploy its Virtual Control Group database for Ipsen to support toxicology studies and reduce animal use.
Ariel Investments, an investment management company, released its “Ariel Appreciation Fund” Q3 2026 investor letter. A copy of the letter can be downloaded here. Copy main article 1st para.
Outsourcing in vivo studies cuts costs and timelines, while AI, advanced imaging and genomics sharpen results. Toxicology and oncology lead, with emerging markets offering cost advantages.Dublin, Oct.
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Madison Investments, an investment advisor, released its “Madison Small Cap Fund” Q3 2026 investor letter. A copy of the letter can be downloaded here.
Charles River Laboratories has outpaced the broader market, and analysts remain optimistic as its next earnings report approaches.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the U.S. Food and Drug Administration (FDA) and Charles River Laboratories to advance the science used to evaluate a medicine's abuse…
Charles River Laboratories International (CRL) drew fresh investor attention after announcing a collaboration with Magellan Stem Cells focused on stem cell therapies and regenerative medicine, supported by biologics quality control and cGMP viral testing.
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Charles River Laboratories (NYSE:CRL) and its peers.
The partnership focuses on biologics quality control as well as viral and release testing under cGMP standards.